Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBIT Margin: 2009-2024

Historic EBIT Margin for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -181.69%.

  • RedHill Biopharma's EBIT Margin rose 322408.00% to 2,992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was -122.98%, marking a year-over-year increase of 7662.00%. This contributed to the annual value of -181.69% for FY2024, which is 37513.00% down from last year.
  • RedHill Biopharma's EBIT Margin amounted to -181.69% in FY2024, which was down 193.92% from 193.45% recorded in FY2023.
  • Over the past 5 years, RedHill Biopharma's EBIT Margin peaked at 193.45% during FY2023, and registered a low of -181.69% during FY2024.
  • For the 3-year period, RedHill Biopharma's EBIT Margin averaged around -19.19%, with its median value being -69.33% (2022).
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 58,776bps in 2020, then skyrocketed by 26,277bps in 2023.
  • RedHill Biopharma's EBIT Margin (Yearly) stood at 98.95% in 2020, then plummeted by 19,356bps to -94.61% in 2021, then skyrocketed by 2,528bps to -69.33% in 2022, then skyrocketed by 26,277bps to 193.45% in 2023, then slumped by 37,513bps to -181.69% in 2024.